UNITY is a biotech company working on the removal of senescent cells, which accumulate with age, drive chronic inflammation, and spur various age-related diseases.
Founded by Drs. Jan van Deursen, Judith Campisi, Nathaniel David, and Daohong Zhou, the company has been developing senolytic therapies that can purge senescent cells from the body without harming healthy cells. The idea is that removing these problem cells could help us to maintain health and remain free of disease as we grow older.
UNITY drug candidate UBX1967 targets specific members of the Bcl-2 family of apoptosis regulatory proteins which some senescent cells use to evade destruction and remain alive.
UBX1967 is being evaluated for the potential treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and proliferative diabetic retinopathy. UNITY plans to submit an IND application and Phase 1 clinical study for an ophthalmological indication in the second half of 2019.
UNITY entered into a license agreement with Ascentage Pharma Group Corp Limited “Ascentage Pharma” in January 2019 granting UNITY exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China for UBX1967 in all non-oncology indications. Inside Greater China, UNITY is obligated to commercialize UBX1967 through a joint venture with Ascentage Pharma.
Website: UNITY Biotechnology